免疫系统
效应器
细胞毒性T细胞
细胞毒性
先天免疫系统
癌症研究
生物
免疫学
抗原
自然杀伤细胞
抗体
细胞
免疫
免疫疗法
癌症免疫疗法
T细胞
B细胞
免疫突触
细胞培养
免疫监视
嵌合抗原受体
免疫受体
胰腺癌
癌症
癌细胞
大肠杆菌
肺癌
作者
Shaobo Yang,Anna Clara Bader,Stephanie Sendker,Ashley Hu,Daniel Chuyang Chen,Hetal Nath,Alice Chen,Eden Bobilev,Michal Sheffer,Veronica Hui,Tereza E. Kochs,Andreia Maia,Jiting Tang,Fuguo Liu,Xingyu Deng,Maily Nguyen,Mila Stanojevic,Mubin Tarannum,Castilleja L. Albert,Alaa Kassim Ali
出处
期刊:
[Cold Spring Harbor Laboratory]
日期:2026-08-20
标识
DOI:10.64898/2026.08.18.745642
摘要
Abstract Despite advances in immunotherapy, most solid tumors remain resistant to treatment. Immune cell engagers redirect cytotoxic lymphocytes against cancer, but limited tumor access, immunosuppressive microenvironments and systemic immune activation limit efficacy. Here we develop live immune modulating engagers (LIME), a modular platform where non-pathogenic, tumor-tropic Escherichia coli display tandem single-chain variable fragments targeting a tumor-associated antigen and an activating receptor on T or natural killer cells. LIME bridged effector and tumor cells, induced transcriptional programs of T cell activation, metabolism and proliferation, and enhanced cytotoxicity across cancer cell lines and patient-derived organoids. In mouse models, LIME safely accumulated in tumors, outperformed tarlatamab in small cell lung cancer, and induced durable immunity in lymphoma. RAS inhibition and PD-L1 blockade enhanced LIME activity in pancreatic cancer and induced humoral responses. Multi-lineage immune modulation remained tumor-confined, without organ toxicity. These findings establish LIME as a versatile living therapeutic platform for programmable, tumor-restricted immune orchestration.
科研通智能强力驱动
Strongly Powered by AbleSci AI